Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

SEC Filings

SEC Filings

Form Description Filing date View
4

Statement of changes in beneficial ownership of securities

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-Q

Quarterly report which provides a continuing view of a company's financial position

EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

Copyright Morningstar



Copyright 2017 - Stemline Therapeutics, Inc. All rights reserved